Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

This study is registered with ClinicalTrials.gov, number NCT02021292.FINDINGS: Between April 3, 2014, and March 17, 2016, we screened 186 patients for eligibility at 48 hospitals across 20 countries. Of these, 80 patients in 36 hospitals were randomly assigned to treatment (40 patients to macitentan, 40 patients to placebo). At week 16, geometric mean PVR decreased to 71·5% of baseline in the macitentan group and to 87·6% in the placebo group (geometric means ratio 0·81, 95% CI 0·70-0·95, p=0·0098). The most common adverse events in the macitentan group were peripheral oedema (9 [23%] of 40 patients) and decreased haemoglobin (6 [15%]).INTERPRETATION: In MERIT-1, macitentan significantly improved PVR in patients with inoperable CTEPH and was well tolerated.FUNDING: Actelion Pharmaceuticals Ltd.PMID:38548406 | DOI:10.1016/S2213-2600(24)00027-4

Source: Respiratory Care - March 28, 2024 Category: Respiratory Medicine Authors: Hossein-Ardeschir Ghofrani G érald Simonneau Andrea M D'Armini Peter Fedullo Luke S Howard Xavier Ja ïs David P Jenkins Zhi-Cheng Jing Michael M Madani Nicolas Martin Eckhard Mayer Kelly Papadakis Dominik Richard Nick H Kim MERIT study investigators Source Type: research